Latest News
Roche expands cyclospora testing portfolio to support US public health response
6 August 2026 - Swiss biotechnology company Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with subsidiary TIB MOLBIOL, announced on Thursday the launch of two new real-time PCR tests to help laboratories detect the Cyclospora cayetanensis para...
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
6 August 2026 - Biotechnology company Olio Labs on Wednesday published research showing that its preclinical in vivo platform predicts human clinical trial outcomes ranging from gastrointestinal adverse events to cardiac toxicity.Rodent studies have ...
Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab
6 August 2026 - China-based biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&D code: TAK-928), a potential first-in-class PD...
Galibra Neuroscience's SSADH deficiency gene therapy receives FDA Orphan Drug and Rare Pediatric Disease Designations
6 August 2026 - Biotechnology research company Galibra Neuroscience announced on Wednesday the receipt of both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for the company&...
Citius Oncology reports growing LYMPHIR adoption and market access
5 August 2026 - Biopharmaceutical company Citius Oncology Inc (Nasdaq: CTOR), a subsidiary of Citius Pharmaceuticals Inc (Nasdaq: CTXR), on Wednesday reported continued commercial progress for LYMPHIR, with the number of new institutional accounts or...